Toxicity of cationic lipids and cationic polymers in gene delivery
- PMID: 16831482
- DOI: 10.1016/j.jconrel.2006.04.014
Toxicity of cationic lipids and cationic polymers in gene delivery
Abstract
Gene therapy, as a promising therapeutics to treat genetic or acquired diseases, has achieved exciting development in the past two decades. Appropriate gene vectors can be crucial for gene transfer. Cationic lipids and polymers, the most important non-viral vectors, have many advantages over viral ones as non-immunogenic, easy to produce and not oncogenic. They hold the promise to replace viral vectors to be used in clinic. However, the toxicity is still an obstacle to the application of non-viral vectors to gene therapy. For overcoming the problem, many new cationic compounds have been developed. This article provides a review with respect to toxicity of cationic lipids and polymers in gene delivery. We evaluate the structural features of cationic compounds and summarize the relationship of toxicity and structure and hope to provide available suggestions on the development of these cationic compounds.
Similar articles
-
Current status of non-viral gene therapy for CNS disorders.Expert Opin Drug Deliv. 2016 Oct;13(10):1433-45. doi: 10.1080/17425247.2016.1188802. Epub 2016 Jun 1. Expert Opin Drug Deliv. 2016. PMID: 27249310 Free PMC article. Review.
-
[Advances in cationic polymers used as nonviral vectors for gene delivery].Sheng Wu Gong Cheng Xue Bao. 2013 May;29(5):568-77. Sheng Wu Gong Cheng Xue Bao. 2013. PMID: 24010355 Review. Chinese.
-
Novel cationic lipids based on malonic acid amides backbone: transfection efficacy and cell toxicity properties.Bioconjug Chem. 2010 Apr 21;21(4):696-708. doi: 10.1021/bc9004624. Bioconjug Chem. 2010. PMID: 20329785
-
Hybrids of nonviral vectors for gene delivery.Bioconjug Chem. 2010 Jun 16;21(6):1003-9. doi: 10.1021/bc900261c. Bioconjug Chem. 2010. PMID: 20205418 Review.
-
Cationic compounds used in lipoplexes and polyplexes for gene delivery.J Control Release. 2004 Nov 24;100(2):165-80. doi: 10.1016/j.jconrel.2004.08.019. J Control Release. 2004. PMID: 15544865 Review.
Cited by
-
Advances in nano-immunotherapy for hematological malignancies.Exp Hematol Oncol. 2024 May 25;13(1):57. doi: 10.1186/s40164-024-00525-3. Exp Hematol Oncol. 2024. PMID: 38796455 Free PMC article. Review.
-
A lipid nanoparticle platform incorporating trehalose glycolipid for exceptional mRNA vaccine safety.Bioact Mater. 2024 May 14;38:486-498. doi: 10.1016/j.bioactmat.2024.05.012. eCollection 2024 Aug. Bioact Mater. 2024. PMID: 38779592 Free PMC article.
-
siRNA incorporated in slow-release injectable hydrogel continuously silences DDIT4 and regulates nucleus pulposus cell pyroptosis through the ROS/TXNIP/NLRP3 axis to alleviate intervertebral disc degeneration.Bone Joint Res. 2024 May 21;13(5):247-260. doi: 10.1302/2046-3758.135.BJR-2023-0320.R1. Bone Joint Res. 2024. PMID: 38771134 Free PMC article.
-
Preparation and Optimization of MiR-375 Nano-Vector Using Two Novel Chitosan-Coated Nano-Structured Lipid Carriers as Gene Therapy for Hepatocellular Carcinoma.Pharmaceutics. 2024 Apr 3;16(4):494. doi: 10.3390/pharmaceutics16040494. Pharmaceutics. 2024. PMID: 38675155 Free PMC article.
-
Exploring the impact of MiR-92a-3p on FOLFOX chemoresistance biomarker genes in colon cancer cell lines.Front Pharmacol. 2024 Apr 10;15:1376638. doi: 10.3389/fphar.2024.1376638. eCollection 2024. Front Pharmacol. 2024. PMID: 38659583 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous